Streptokinase for acute ischemic stroke with relationship to time of administration

JAMA

Volumn 276, Issue 12, 1996, Pages 961-966

  Donnan, Geoffrey A ^a   Davis, Stephen M ^b   Chambers, Brian R ^a   Gates, Peter C ^c   Hankey, Graeme J ^d   McNeil, John J ^e   Rosen, David ^f   Stewart Wynne, Edward G ^d   Tuck, Roger R ^g  

^a AUSTIN HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c GEELONG HOSPITAL   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g WODEN VALLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIPRIN; STREPTOKINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

EID: 0029842750     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.12.961     Document Type: Article

References (34)

1. del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic Therapy in Acute Ischaemic Stroke II. Berlin, Germany: Heidelberg Springer-Verlag; 1993.
2. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992; 42:976-982.
3. del Zoppo GJ, Copeland BR, Waltz TA, Zyroff J, Plow EF, Harker LA. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke. 1986;17:638-643.
4. Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator, reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 1988;45:387-391.
5. Zeumer H, Hundgen R, Ferbert A, Ringelstein EB. Local intra-arterial fibrinolytic therapy in inaccessible internal carotid occlusion. Neuroradiology. 1984;26:315-317.
6. Henze T, Boeer A, Tebbe U, Romatowski J. Lysis of basilar artery occlusion with tissue plasminogen activator. Lancet. 1987;2:1391.
7. del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. Stroke. 1988;19:307-319.
8. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;19: 802-812.
9. Hacke W, Zeumer H, Ferbert A, Buckmann H, del Zoppo GJ. Intra-arterial fibrinolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19:1216-1222.
10. Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolie stroke. Cerebrovasc Dis. 1993;3:269-272.
11. Hacke W, Kaste M, Fieschi C, et al, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
13. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346: 1509-1514.
14. The Multicentre Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
16. Donnan GA, Davis SM, Chambers BR, et al. Australian Streptokinase Trial (ASK). In: del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic Therapy in Acute Ischaemic Stroke 11. Berlin, Germany: Springer-Verlag; 1993:80-85.
17. Petito CK. Early and late mechanisms of increased vascular permeability following experimental cerebral infarction. J Neuropathol Exp Neurol. 1979;38:222-234.
18. Bell BA, Simon L, Branston NM. CBF and time thresholds for the formation of ischemic cerebral oedema and effect of reperfusion in baboon. J Neurosurg. 1985;62:31-41.
19. Hallenbeck JM, Dutka AJ. Background review and current concepts of reperfusion injury. Arch Neurol 1990;47:1245-1254.
20. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction: a prospective study. Stroke. 1986;17:179-185.
21. Okada Y, Yamaguchi T, Minematsu K, et al. Hemorrhagic transformation in cerebral embolism. Stroke. 1989;20:598-603.
22. Slivka A, Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke. 1987;18:1148-1156.
23. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:723-725.
24. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet. 1995;345:578-579.
25. Cote R, Hachinski CH, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke. 1986; 17(4):731-737.
26. Leftkovits J, Davis SM, Rossiter SC, et al. Acute stroke outcome: effects of stroke type and risk factors. Aust N Z J Mod. 1992;22:30-35.
27. Hain RF, Westhaysen PV, Swank RL. Hemorrhagic cerebral infarction by arterial occlusion: an experimental study. J Neuropathol Exp Neurol. 1952;11:34-43.
28. Jorgensen L, Torvik A. Ischemic cerebrovascular diseases in an autopsy series, part 2: prevalence, focation, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci. 1969;9:286-320.
29. Crowell EM, Oisson Y, Klatzo I, Ommaya A. Temporary occlusion of the middle cerebral artery in the monkey: clinical and pathological observations. Stroke. 1970;1:439-448.
30. Kamijyo Y, Garcia JH, Cooper J. Temporary regional cerebral ischemia in the cat: a model of hemorrhagic and subcortical infarction. J Neuropathol Exp Neurol. 1977;36:338-351.
31. Zivin JA, Fisher M, DeGirolami U. Tissue plasminogen activator reduces neurological damage: after cerebral embolism. Science. 1985;320:1289-1292.
32. Verstraete M, Gollen D. Thrombolytic therapy in the eighties. Blood. 1986;67:1529-1541.
33. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke, part 1: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
34. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke, part II: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.